ARTICLE | Finance
Bile be gone
With $23M, Lumena looks to advance liver disease compound through Phase II
May 13, 2013 7:00 AM UTC
Lumena Pharmaceuticals Inc. is looking to advance its lead compound LUM001 through three Phase II cholestatic liver disease trials with funds from its $23 million series A.
President and CEO Mike Grey said the company plans to start the trials this year in three Orphan indications: adults with primary biliary cirrhosis (PBC); children with Alagille syndrome; and children with progressive familial intrahepatic cholestasis...